Could a diabetes drug also mend hearts? new study in kazakhstan investigates

NCT ID NCT07303556

Ongoing Disease control Sponsor: Nazarbayev University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a dual GIP/GLP-1 drug (a type of diabetes medication) in 120 adults in Kazakhstan who have both chronic heart failure and type 2 diabetes. Participants take the drug for 40 weeks and have regular heart tests, blood work, and genetic checks. The goal is to see if the drug improves heart function, blood sugar, and weight, and to understand how genetics affect response.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ARTERIAL HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diastolic heart failure essential hypertension heart failure hypertensive disorder type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ARTERIAL HYPERTENSION DIABETE TYPE 2 HEART FAILURE

Contacts and locations

Locations

PI "National Laboratory Astana", Nazarbayev University

Astana, Kazakhstan, 010000, Kazakhstan

More trials for these conditions

Other studies related to the condition(s) this trial covers.